Big Pharma Braces for More FTC Suits Over M&A Bound for Approval

The pharmaceutical sector is preparing for more antitrust litigation after a pivot by US regulators to lawsuits that prioritize clarifying the law over successfully blocking deals.

Recent actions by the Federal Trade Commission under Chair Lina Khan that include a review of Pfizer Inc.‘s $43 billion takeover of Seagen Inc. have overturned settled practices for the agency, signaling a greater willingness to litigate in an attempt to set precedents that define anticompetitive conduct, according to academics and a former FTC director.

The FTC announced Thursday it would engage in data sharing with the Justice Department and the Department of ...